English  |  正體中文  |  简体中文  |  Post-Print筆數 : 27 |  Items with full text/Total items : 113318/144297 (79%)
Visitors : 51035526      Online Users : 935
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: https://nccur.lib.nccu.edu.tw/handle/140.119/101026


    Title: 由AMP v. Myriad Genetics, Inc.案談基因專利之適格性
    Other Titles: Gene Patents in the Aftermath of AMP v. Myriad Genetics, Inc.
    Authors: 李治安
    Lee, Jyh-An
    Keywords: 基因檢測;基因專利;DNA序列;cDNA序列;第二意見
    genetic test;gene patent;DNA sequence;cDNA sequence;second opinion
    Date: 2014-12
    Issue Date: 2016-08-31 17:11:16 (UTC+8)
    Abstract: 本文以美國聯邦最高法院於Association for MolecularPathology v. Myriad Genetics, Inc.案判決為中心，探討基因技術之專利適格問題，本文首先概述美國聯邦最高法院歷年就專利適格所作之重要判決，接著於介紹Myriad案歷審判決，該案歷審法院之法律見解各有所重，判決結果亦有相當差異，某種程度呈現了基因專利問題之複雜性與爭議性。由於專利制度係採屬地主義，因此國際企業就重要技術均會於不同法域申請專利，而不同法域之司法及審查機關對相同專利技術有時會採取不同見解，本案Myriad公司關於基因技術之系爭專利亦曾於歐洲及澳洲引發爭議，該等法域之司法判決於本案討論亦有相當參考價值，因此本文亦將析述之。最後，本文由自然產物之可專利性、專利法促進創新之制度目的、病患權益維護、專利法與科學之關連及專利與營業秘密之策略選擇等角度，分析本案所涉及的專利政策及策略意涵。
    The U.S. Supreme Court`s decision on Association for Molecular Pathology v. Myriad Genetics, Inc. has drawn wide attention from the academia and the biomedical industries. The most controversial issue underlying the decision is the patentability of isolated DNA and cDNA. This study first introduces a series of U.S. Supreme Court decisions on patentability and the subject matter issues. By providing an overview of the Myriad case decisions, from the district court to the Supreme Court, this Article illustrates the complicated legal issues associated with gene patenting. Interestingly, the European and Australia authorities have had different perspectives on the patentability of Myriad`s technologies, which are analyzed in the Article from a comparative perspective. Furthermore, this paper explores a number of policy implications from the Myriad case, including the patentability of product of nature, patent and innovation, and the protection of patients. This Article uses the Myriad case to illustrate the complicated interaction between science and the patent system. Finally, Myriad`s IP strategy after the Supreme Court decision also presents the tricky interface between patent protection and trade secret protection.
    Relation: 政大智慧財產評論, 12(2), 1-46
    NCCU Intellectual Property Review
    Data Type: article
    Appears in Collections:[智慧財產評論] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML2879View/Open


    All items in 政大典藏 are protected by copyright, with all rights reserved.


    社群 sharing

    著作權政策宣告 Copyright Announcement
    1.本網站之數位內容為國立政治大學所收錄之機構典藏，無償提供學術研究與公眾教育等公益性使用，惟仍請適度，合理使用本網站之內容，以尊重著作權人之權益。商業上之利用，則請先取得著作權人之授權。
    The digital content of this website is part of National Chengchi University Institutional Repository. It provides free access to academic research and public education for non-commercial use. Please utilize it in a proper and reasonable manner and respect the rights of copyright owners. For commercial use, please obtain authorization from the copyright owner in advance.

    2.本網站之製作，已盡力防止侵害著作權人之權益，如仍發現本網站之數位內容有侵害著作權人權益情事者，請權利人通知本網站維護人員(nccur@nccu.edu.tw)，維護人員將立即採取移除該數位著作等補救措施。
    NCCU Institutional Repository is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff(nccur@nccu.edu.tw). We will remove the work from the repository and investigate your claim.
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback